TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05821556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: The treatment should be started within 3 days from randomization. One cycle consisted of 28 days of treatment for both arms. Patients will continue to receive study treatment up to 6 cycles until disease progression, unacceptable toxicity, physician's decision, patient's refusal, or any other discontinuation criteria. Continuation of treatment, over the six cycles, will be allowed only in case of clinical benefit, defined as continuous decrease of CA19-9 concentration or radiological response, without unacceptable toxicity.~All subjects who finish treatment, whichever the reason, will enter in the follow-up. We expect that for the primary endpoint, PFS, follow-up will last up to 10 months after enrollment.~Anyhow, all subjects will be followed until death and data on subsequent treatment will be collected.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: The treatment should be started within 3 days from randomization. One cycle consisted of 28 days of treatment for both arms. Patients will continue to receive study treatment up to 6 cycles until disease progression, unacceptable toxicity, physician's decision, patient's refusal, or any other discontinuation criteria. Continuation of treatment, over the six cycles, will be allowed only in case of clinical benefit, defined as continuous decrease of CA19-9 concentration or radiological response, without unacceptable toxicity.~All subjects who finish treatment, whichever the reason, will enter in the follow-up. We expect that for the primary endpoint, PFS, follow-up will last up to 10 months after enrollment.~Anyhow, all subjects will be followed until death and data on subsequent treatment will be collected.
Study: NCT05082168

Intervention type: DEVICE
Intervention: Capnodynamic monitoring
Description: In patients fully synchronized with mechanical ventilation, the capnodynamic method calculates the effective pulmonary blood flow, the end-expiratory lung volume and estimates the mixed venous oxygen saturation. The capnodynamic method uses short inspiratory or expiratory pauses to induce small changes in CO2 concentration the enable the mole balance to be resolved for the capnodynamic equation:~ELV x \[(FACO2(n)-FACO2(n-1)\] = delta(n) x EPBF \[CvCO2(n)\] - VTCO2.

Intervention type: DEVICE
Intervention: Capnodynamic monitoring
Description: In patients fully synchronized with mechanical ventilation, the capnodynamic method calculates the effective pulmonary blood flow, the end-expiratory lung volume and estimates the mixed venous oxygen saturation. The capnodynamic method uses short inspiratory or expiratory pauses to induce small changes in CO2 concentration the enable the mole balance to be resolved for the capnodynamic equation:~ELV x \[(FACO2(n)-FACO2(n-1)\] = delta(n) x EPBF \[CvCO2(n)\] - VTCO2.
Study: NCT04578171

Intervention type: DRUG
Intervention: Mepolizumab
Description: 100 mg subcutaneous injections every four weeks
Study: NCT05218200

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: deep breathing and coughing exercises with triflo
Description: patients will be given triflo. A video of the application of deep breathing and coughing exercises with triflo prepared by the researchers will be prepared. The video will be sent to the patients' phones. It will be ensured that the patients do the exercises every hour by watching the video and they will be followed.
Study: NCT06291766

Intervention type: DEVICE
Group type: OTHER
Intervention: FreeStyle Libre 2, continous glucose monitoring
Description: The use of FreeStyle Libre 3 sensors and Libre Link app and Glooko app for analysing glucose control in pregnancy
Study: NCT04428385

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Testing incentive
Description: A small incentive will be paid to the provider each time they perform a malaria rapid diagnostic test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conditional artemisinin combination therapy subsidy
Description: An additional discount on WHO-approved quality assured ACTs will be offered to individuals with a positive RDT.
Study: NCT04767113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin sodium
Description: For infants without thrombosis at enrollment, heparin 1 U/kg/h/line for term infants was used and 0.5 U/kg/h/line for preterm infants. The speed of infusion was 0.5ml/h.~For infants with thrombosis at enrollment, heparin 10-15 U/kg/h for term infants was used with a target activated partial thromboplastin time 60-70s. Other interventions were at the clinical team's discretion under the local protocol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: For infants enrolled, normal saline was infused at the corresponding speed.
Study: NCT06499194

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: DASH diet
Description: The Dietary Approaches to Stop Hypertension (DASH) diets rich in fruits and vegetables and reduced in saturated fat can lower the risk for high blood pressure and assist with blood pressure control in hypertensive persons

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DASH diet
Description: The Dietary Approaches to Stop Hypertension (DASH) diets rich in fruits and vegetables and reduced in saturated fat can lower the risk for high blood pressure and assist with blood pressure control in hypertensive persons
Study: NCT06434194

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Serranator PTA Serration Catheter
Description: The Serranator PTA Serration Balloon Catheter is an over-the-wire balloon dilatation catheter designed to perform percutaneous transluminal angioplasty (PTA) for peripheral indications.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTA (Standard of Care)
Description: A percutaneous transluminal angioplasty catheter will be used to treat the target lesion.
Study: NCT05558319

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isatuximab
Description: Isatuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Isatuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Isatuximab
Study: NCT05082168

Intervention type: DEVICE
Intervention: Capnodynamic monitoring
Description: In patients fully synchronized with mechanical ventilation, the capnodynamic method calculates the effective pulmonary blood flow, the end-expiratory lung volume and estimates the mixed venous oxygen saturation. The capnodynamic method uses short inspiratory or expiratory pauses to induce small changes in CO2 concentration the enable the mole balance to be resolved for the capnodynamic equation:~ELV x \[(FACO2(n)-FACO2(n-1)\] = delta(n) x EPBF \[CvCO2(n)\] - VTCO2.
Study: NCT05914870

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-component training
Description: The multicomponent training group will perform 60 minutes of training per session:~* 10 minutes of joint mobility exercises and dynamic stretching.~* 20 minutes of strength work with 2 exercises; the first, bench press, at an intensity of 50% of your 1RM. The number of repetitions will be individualised for each subject by testing the loss of speed in the series with respect to the first repetition (15% loss); the second, the squat, at an intensity of 60% of your 1RM. The number of repetitions shall be individualised for each subject by means of the loss of speed test in the series with respect to the first repetition (10% loss). The rest between sets will be 3 minutes.~* 20 minutes of continuous cardiovascular work. The intensity will be increased every 4 weeks, from week 1 to 4 between 55%-65%FCR or VO2peak, from week 5 to 8 between 65%-%75%FCR or VO2peak and from week 9 to 12 between 75%-%85%FCR or VO2peak.~* 10 minutes of cool down and static stretching.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous Cardiovascular Training
Description: The Continuous Cardiovascular Training group will perform 60 minutes of training per session distributed as follows:~Preparatory Phase: 10 minutes of standardised warm-up with joint mobility exercises and dynamic stretching.~Main Training Phase:~In this phase we will work 40 minutes of continuous aerobic exercise, maintaining the same intensity range throughout the session. We will increase the intensity every 4 weeks, from 1 to 4 you will work between 55%-65%FCR or VO2peak, from 5 to 8 between 65%-%75%FCR or VO2peak and from 9 to 12 between 75%-%85%FCR or VO2peak.~Post-training phase: 10' cool down and static stretching.
Study: NCT05558319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Iberdomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Iberdomide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone
Study: NCT04996966

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human umbilical cord-derived mesenchymal stem cells
Description: In the MSCs injection group, 1×10\^6/kg human umbilical cord-derived mesenchymal stem cells were intravenously injected to the patient immediately after the surgery and at day 3 after the surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: In the control group, saline containing 2% albumin (2ml/kg) were intravenously injected to the patient immediately after the surgery and at day 3 after the surgery.
Study: NCT05959265

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: Patients in the treatment group will undergo a 12-week intervention consisting of three 30-minute walking exercises per week during their standard cancer treatment. A personalized walking plan using fitness trackers will be provided to record each patient's daily average heart rate, step count, and additional steps and heart rate during the three 30-minute walking exercises per week to assess their activity levels. Weekly collaborations between the principal investigator and each participant will be conducted to assess step-related parameters.
Study: NCT05090202

Intervention type: DIAGNOSTIC_TEST
Intervention: hbA1C
Description: hbA1C will be measured for all patients and results will be analysed into Non diabetic, Prediabetic and Diabetic

Intervention type: DIAGNOSTIC_TEST
Intervention: hbA1C
Description: hbA1C will be measured for all patients and results will be analysed into Non diabetic, Prediabetic and Diabetic

Intervention type: DIAGNOSTIC_TEST
Intervention: hbA1C
Description: hbA1C will be measured for all patients and results will be analysed into Non diabetic, Prediabetic and Diabetic
Study: NCT05821387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucid-21-302
Description: A small molecule inhibitor of hypercitrullination

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Product containing excipients with no active ingredients
Study: NCT04717258

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fire and Rescue Service Safe and Well Visit
Description: Safe and Well Visits by the Fire and Rescue Service to prevent falls and improve quality of life in an older population

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Determination Theory informed trial invitation letter
Description: Invitation letter to take part in the FIREFLI study informed by Self-Determination Theory

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pen included with reminder questionaire
Description: A pen will be included with the four-month reminder questionnaire.
Study: NCT06522464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group A: mCIMT with cross-education
Description: For ten weeks, Group A will follow the mCIMT Protocol, which entails 30 minutes of one-on-one therapy three days a week and five hours a day (weekdays) of constraint.~In addition, the student will receive extra cross-education, which will involve practicing reaching tasks, wrist flexion and extension, and non-paretic hand opening and closing for 30 minutes. Activities include building a tower out of cubes in various colors, sorting cubes of similar colors and forms together (square cubes in a column, cylindrical cubes together), gripping a hammer, and various cube and triangular shapes. putting balls in their column, placing various-sized circular forms in their proper locations, and moving items between both hands (18). We'll utilize weight cuffs for every activity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group B: mCIMT without cross-education
Description: For ten weeks, Group B will follow the mCIMT Protocol, which entails 30 minutes of one-on-one therapy three days a week and five hours a day (weekdays) of confinement.
Study: NCT06108518

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carvedilol
Description: Treatment group will take carvedilol 12.5mg once a day for 2 days; this is increased to 25 mg once a day or 12.5 mg twice a day for 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: Treatment group will take carvedilol 12.5mg once a day for 2 days; this is increased to 25 mg once a day or 12.5 mg twice a day for 3 months.
Study: NCT06363643

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELECTROSTIMULATION (ES)
Description: ES will receive the electrostimulator directly at home and will do three weekly Tele supervised sessions of 30 minutes of indirect electrostimulation. The treatment will last 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EXERCISE (C)
Description: C will perform three weekly Tele supervised sessions of exercise. The treatment will last 4 weeks.
Study: NCT04546633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAF156
Description: Provided as 50 mg or 100 mg tablets, to be taken QD 2 or 3 Days in combination with LUM-SDF, dose is based on body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAF156
Description: Provided as 50 mg or 100 mg tablets, to be taken QD 2 or 3 Days in combination with LUM-SDF, dose is based on body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAF156
Description: Provided as 50 mg or 100 mg tablets, to be taken QD 2 or 3 Days in combination with LUM-SDF, dose is based on body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM-SDF
Description: Provided as 60 mg, 120 mg or 240 mg powder in sachet, to be taken QD 2 or 3 Days in combination with KAF156, dose is based on body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM-SDF
Description: Provided as 60 mg, 120 mg or 240 mg powder in sachet, to be taken QD 2 or 3 Days in combination with KAF156, dose is based on body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM-SDF
Description: Provided as 60 mg, 120 mg or 240 mg powder in sachet, to be taken QD 2 or 3 Days in combination with KAF156, dose is based on body weight

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coartem
Description: Coartem® (dispersible tablets in blister pack) (for Cohorts 1 and 2), dose is based on body weight
Study: NCT05399199

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: virtual reality distraction
Description: study group patients will view VR scene for 6 minutes before puncture .It involves a soothing nature experience and calming background music. Patients in intervention group will not able to see the puncture procedure due to the VR glasses.
Study: NCT05340335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: A beginning dose of remimazolam is 1mg/kg/hr. When sedation is not achieved in 10 minutes, the dose will be increased by 0.1mg/kg/hr in the next patient. When sedation is successful, the same dose will be used with the probability of 0.89, or the dose will be decreased by 0.1mg/kg/hr with the probability of 0.11 in the next patient. (maximal dose: 2mg/kg/hr)
Study: NCT05682417

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Body Map Assessment Tool: MOVE Tool
Description: In VR, a spherical object approaches with linear trajectory the body of patients, it can be sent to 4 parts of the body (mid-arm/waist/hip/mid-thigh) both left and right side. Several conditions are presented, either the trajectory leads the object to touch the body, or it passes at ≠ distances from it. Patient is instructed to move only if he thinks the object will touch his body.~Procedure begins with a measurement taken on 3 body locations via the Move tool (shoulders/hips/thighs) to create an avatar allowing the tool to determine whether or not movement was necessary. Then, the movement of the patient is recorded. For each object/body distance, the software determines if dodging was necessary. The overestimation of the body schema corresponds to the average distance from which the patient considers that the object would have touched her body and performs a dodging movement, compared to her real morphological dimensions. This generates a body limit distortion % for each body area.
Study: NCT04997096

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 16-week, virtually supervised, technology-based, aerobic and resistance exercise program performed 3 days per week which starts at least 4 weeks after surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Home-based stretching program consisting of one set of 4 static stretching exercises held for 30 seconds and performed 3 days/week. Participants will be shown how to use the booklet and instructed on how to complete the stretching exercises by an exercise trainer.
Study: NCT05726240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ghrelin
Description: Treatment in the intervention group will consist of intravenous acylated ghrelin, 600micrg dissolved in 50cc normal saline, by bolus (short term) infusion in 30 minutes, twice daily, for five days. This treatment will be additional to standard treatment, including intravenous thrombolysis, if indicated.
Study: NCT06303258

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Stabalization Exercises
Description: Low Intensity Warm Up Exercises Core Stabilization Exercises Cool Down Stretching Exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Generalized Antenatal Exercises
Description: Low Intensity WarmUp Exercise Aerobic Training Endurance Training Pelvic Floor Muscle Training Cool Down Stretching Exercises
Study: NCT04553562

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Sterile adhesive pads will be placed after skin disinfection on the acupoints. Guanyuan (CV4)，Qihai (CV6)，bilateral Sanyinjiao (SP6), Yinbao (LR9), Qixue (KI13) and Fujie (SP14) will be inserted through the pads by the needles (0.30mm in diameter, 40 mm in length, Hwato Brand, Suzhou Medical Appliance Factory, China) to a depth of 25-30mm. Yintang (GV4) will be inserted through the pads by the needle (0.30mm in diameter, 25mm in length, Hwato Brand, Suzhou Medical Appliance Factory, China) to a depth of 10-15mm. The needles at all points will be lightly lifting, thrusting, and twirling every 10 minutes during each session with the sensation of sourness, achiness, heaviness and numbness (deqi). The participants will be treated three times a week, on alternate days (ideally), for 6 successive weeks; 18 sessions for each patient in total.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Sterile adhesive pads will be placed after skin disinfection on the acupoints. Needles (0.30 mm in diameter, 25 mm in length) with a blunt tip will be inserted at the Guanyuan (CV4)，Qihai (CV6)，bilateral Sanyinjiao (SP6), Yinbao (LR9), Qixue (KI13) and Fujie (SP14) without penetrating the skin. The participants will be treated three times a week, on alternate days (ideally), for 6 successive weeks; 18 sessions for each patient in total.
Study: NCT05530772

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic necrosectomy
Description: Initially, a tract is created between the stomach or duodenum with the walled-off pancreatic necrotic collection through placement of a stent. Then, the endosocpe is entered the necrotic cavity with CO2 insufflation, and the necrotic materials are removed with snare, grasper, or suctioning.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic necrosectomy
Description: Initially, a tract is created between the stomach or duodenum with the walled-off pancreatic necrotic collection through placement of a stent. Then, the endosocpe is entered the necrotic cavity with CO2 insufflation, and the necrotic materials are removed with snare, grasper, or suctioning.
Study: NCT05397197

Intervention type: OTHER
Group type: OTHER
Intervention: Electroencephalography
Description: experimental task, neuropsychological evaluation, clinical exam
Study: NCT06040814

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation Training
Description: 12 week Rehabilitation Training course
Study: NCT05238636

Intervention type: PROCEDURE
Intervention: Anti-reflux surgery - Stretta procedure or LINX device or laparoscopic fundoplication
Description: This is an observational study. Patients will choose which anti-reflux procedure (Stretta, LINX or fundoplication) they undergo with their clinician, as is standard practice, after which they will be offered recruitment to this study, which will perform investigations to assess for changes in physiology and symptoms.

Intervention type: PROCEDURE
Intervention: Anti-reflux surgery - Stretta procedure or LINX device or laparoscopic fundoplication
Description: This is an observational study. Patients will choose which anti-reflux procedure (Stretta, LINX or fundoplication) they undergo with their clinician, as is standard practice, after which they will be offered recruitment to this study, which will perform investigations to assess for changes in physiology and symptoms.

Intervention type: PROCEDURE
Intervention: Anti-reflux surgery - Stretta procedure or LINX device or laparoscopic fundoplication
Description: This is an observational study. Patients will choose which anti-reflux procedure (Stretta, LINX or fundoplication) they undergo with their clinician, as is standard practice, after which they will be offered recruitment to this study, which will perform investigations to assess for changes in physiology and symptoms.